10 times bull stock factory explosion, main business involves a number of A-share companies

 10 times bull stock factory explosion, main business involves a number of A-share companies

According to the companys relevant person in charge, the main management and relevant local government departments are working on the spot, and the corresponding results will be disclosed in the morning of July 28. The above-mentioned explosion news was confirmed by e company from Taizhou late on the 27th.

Main business cooperation with Hengrui pharmaceutical, Beilu pharmaceutical, etc

Stili is a pharmaceutical high-tech enterprise, mainly engaged in the production of pharmaceutical characteristic raw materials, the main products are non-ionic iodine contrast agent, quinolone antibacterial drugs and other drug raw materials and intermediates research and production. The main products of the companys iodine contrast agent raw materials are iohexol, iodofol, iodixanol, etc.; the main products of quinolones are levofloxacin, levofloxacin hydrochloride, etc.

Contrast agent, also known as contrast agent, is used in medical imaging, which can increase the contrast of subjects images. It is mainly used in cardiovascular and tumor diseases. At present, contrast agents are mainly divided into X-ray contrast agents, magnetic resonance contrast agents and ultrasound contrast agents.

According to the data of Newport premium, as of 2018, the global contrast medium market scale is 6.08 billion US dollars, of which x-ray contrast agent occupies the main part of the global contrast agent market.

According to the relevant data of China Pharmaceutical Industry Information Center, iohexol, barium sulfate and ioparol are the best-selling contrast agents in the world at present, followed by iodixanol, iopromide and ioversol. Among them, iohexol market scale is far ahead, followed by iodofol and iodixanol, and the market scale of iopromide, ioversol and iodophor is relatively close Near. These six varieties are all non-ionic organic iodine compounds, and their market share in the global market of X-ray contrast agents is approaching 90%.

At present, the main production / import of X-ray contrast agents in China are Hengrui pharmaceutical, gehealthcare, Bracco, Bayer, Yangzi River Pharmaceutical, Beilu pharmaceutical, etc., of which the top three account for the majority of the domestic market.

By the end of 2019, stili has established cooperative relations with major domestic manufacturers of iodine contrast agent preparations, such as Hengrui pharmaceutical, Beilu pharmaceutical, Yangzijiang pharmaceutical and foreign generic pharmaceutical enterprises such as Fuji of Japan.

According to the data, in 2019, steli achieved a revenue of 1.309 billion yuan, a year-on-year increase of 46.98%; the net profit attributable to shareholders of listed companies was 170 million yuan, with a year-on-year increase of 81.83%. In the first quarter of 2020, the company realized 291 million yuan of operating revenue, with a year-on-year growth of - 0.95%; the net profit attributable to shareholders of listed companies was 45.655 million yuan, with a year-on-year increase of 11.83%.

The financing plan of additional issuance has just been approved

After the explosion, whether the newly approved additional issue financing can be carried out as scheduled affects the capital market.

On July 2, steli announced that the company had recently received the reply on the approval of non-public development of shares of Zhejiang steli Pharmaceutical Co., Ltd. issued by the China Securities Regulatory Commission (CSRC), which approved the company to issue no more than 70.4868 million new shares in a non-public way; the reply was valid within 12 months from the date of approval of issuance.

The official reply also pointed out that from the date of approval of the issuance to the end of this stock issue, if the company has any major events, it shall report to the SFC in time and deal with it in accordance with relevant regulations.

The above-mentioned additional issue financing of steli started at the end of 2019. In November 2019, the company started to refinance. The number of shares to be issued in private is not more than 33.5797 million shares, and the total amount of funds raised (including the issuance expenses) does not exceed 672 million yuan.

However, in March 2020, the companys above-mentioned plan for additional issuance will be adjusted to no more than 5036.95 shares (from October to four in 2020), and the objects of additional issuance will be adjusted to no more than 35 specific investors.

The raised funds will be used for the annual output of 1500 tons of iodide and R & D quality inspection center, 300 tons of ioversol and 5 tons of gadolinium beta meglumine contrast agent API, 195 tons of customized pharmaceutical intermediates, 1200 tons of triiodoisphthaloyl chloride, improvement and transformation of environmental protection facilities and supplementary working capital.

In addition, Stanleys stock bar also blew up, and investors began to talk about the future market trend. Some said that they felt at the scene of the accident, the factory building exploded, the doors and windows of the houses around it vibrated violently, and said that it would drop to the limit tomorrow. But optimists say, as long as its not the companys performance. Any sudden news is a golden pit, reverse thinking.

From the position in the first quarter of this year, the top ten circulating shareholders of steli are relatively stable. Among them, the positions of 4 institutions, including lonson investment (Hong Kong) Co., Ltd., remained unchanged, and only 2 companies, including Ruiyi investment, Panshan VII private equity investment fund, reduced their holdings of about 580000 shares in total.

Source: Securities Times editor in charge: Yang Bin_ NF4368